A Prospective, Multicenter, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when given in combination with Paclitaxel in patients diagnosed with HER2 Positive Metastatic Breast Cancer
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Trastuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 11 Sep 2017 Status changed from not yet recruiting to recruiting.
- 09 Mar 2017 New trial record